



**sirona**  
biochem

# Investor Presentation

November 2019

ADVANCING CHEMISTRY.  
ENHANCING HEALTH.™

# Forward Looking Statements

*Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.*

# Sirona's Technology Platform

- Sirona Biochem, through our wholly owned subsidiary, TFChem, has developed safer, more effective cosmetic and pharmaceutical active ingredients.
- Sirona Biochem specializes in the stabilization of carbohydrate molecules to improve their efficacy and safety.



# Sirona's Technology Platform

## Because carbohydrates have huge potential

- Carbohydrates are involved in many of our body's biological processes.
- Examples of carbohydrate-based drugs are the viral neuraminidase inhibitors, **Relenza** and **Tamiflu**, which are both used for the treatment of Influenza A.
- Several synthetic heparins are approved as anticoagulants, such as **Arixtra** and **Lovenox**.

# Why we do it

## However...

- Development and commercialization lag due to major drawbacks:
  - Complex synthesis
  - Instability – causing lower efficacy or toxic by products
  - Poor pharmacological properties


**Our solution increases the potential and reduces the drawbacks of carbohydrate molecules**

# How we do it


- Sirona's Fluorination Chemistry Technology is the solution to unstable carbohydrate molecules.
- We strengthen the bond of a carbohydrate molecule by strategically placing fluorine atoms within the molecule.



# How we do it



**Carbohydrate molecules are unstable by nature**



**Our technology stabilizes carbohydrate molecules**


**Resulting in improved bioavailability and selectivity that translates into better safety and efficacy**

# How we create revenue

- Sirona's strategy is to license or sell our patented compounds to leading global companies in return for up-front fees, milestone fees and ongoing royalty payments.
- Our SGLT2 inhibitor for diabetes has been licensed to Wanbang/Fosun Pharmaceutical in China and is approved by the CFDA to enter Phase I.
- Our skin lightening compound TFC-1067, has been licensed to industry leader, Rodan + Fields in a non-exclusive agreement, allowing us to continue seeking further global partners
- In parallel, we are advancing our novel anti-wrinkle compound.



# Global Skin Lightening Market



# Pipeline With Focus On Partnering

## Cosmetic Products

| Therapeutic Area                    | Compound                                | Partnering Status  |
|-------------------------------------|---|--|
| Skin lightening (Rx & OTC)          | TFC-1067<br>& family of skin lighteners | Rodan + Fields licensed<br>Seeking further global partners |
| Cell Preservation &<br>Anti-Wrinkle | Various                                 | In R&D   |

## Pharmaceutical Products

| Therapeutic Area | Compound | Partnering Status                                     |
|------------------|----------|---|
| Diabetes         | TFC-039  | Wanbang / Fosun (China)<br>Ready for licensing in ROW |

# Locations



**Sirona Biochem (Parent Company)**  
Vancouver, BC, Canada

**TFChem (Wholly Owned Subsidiary)**  
Cosmetic Valley, France

- Sirona Biochem was founded in 2009
- TFChem was acquired in 2011



# Management Team



**Howard J. Verrico, MD**  
CEO and Chairman of the Board



**Geraldine Deliencourt-Godefroy, PhD**  
Chief Scientific Officer



**Christopher Hopton, CPA, CGA**  
Chief Financial Officer



**Michelle Seltenrich, MBA, BSc**  
VP, Operations

# Investment Highlights

- Sirona Biochem has licensed its skin lightener, TFC-1067, to Rodan + Fields. The compound, which was tested in a clinical trial in the USA, was shown to be better than 2% Hydroquinone for Dyschromia (<https://bit.ly/2XJmckK>)
- Sirona Biochem is seeking further partnering opportunities for TFC-1067
- The Company's diabetes drug, TFC-039, is partnered with Wanbang/Fosun and is currently in development for the Chinese market
- Development of an anti-wrinkle therapy with a novel mechanism of action

# Share Capital\*

Shares Issued & O/S: 222,905,003

Stock Options: 6,020,000

Warrants - \$0.18 strike exp 16/10/2021: 7,190,420

Warrants - \$0.16 strike exp 27/02/2022: 17,835,000

Warrants - \$0.60 strike exp 16/07/2022: 3,750,000

Shares Issued (Fully Diluted): 261,803,868

Market Cap: \$91.3 Million

\*as of November 2019